ArticlePigment cell & melanoma research2017
MicroRNA-125a promotes resistance to BRAF inhibitors through suppression of the intrinsic apoptotic pathway.
Abstract read
In one paragraph
Article in Pigment cell & melanoma research, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 34 papers.
0numbers the graph read from it
0cells of the map it votes in
34citing papers in PubMed
1.9field-weighted citation impact, top 14% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
34 citing papers in PubMed, 45 citations in OpenAlex.
- SOX10-mediated regulation of the MiR-106a/363 cluster drives RAF inhibitor resistance in BRAF-mutant melanoma.Cellular and molecular life sciences : CMLS · 2026Article
- Tumor miRNA Signatures Associate with Outcomes of Patients with Stage II/III Melanoma.Clinical cancer research : an official journal of the American Association for Cancer Research · 2025Article
- Omics in Cutaneous Melanoma.Asian Pacific journal of cancer prevention : APJCP · 2025Review
- Diagnostic Power of MicroRNAs in Melanoma: Integrating Machine Learning for Enhanced Accuracy and Pathway Analysis.Journal of cellular and molecular medicine · 2025Article
- Non-coding RNAs in BRAF-mutant melanoma: targets, indicators, and therapeutic potential.Naunyn-Schmiedeberg's archives of pharmacology · 2025Review
- Advances in Understanding Drug Resistance Mechanisms and Innovative Clinical Treatments for Melanoma.Current treatment options in oncology · 2024Review
- TGF-β Modulated Pathways in Colorectal Cancer: New Potential Therapeutic Opportunities.International journal of molecular sciences · 2024Review
- Article
- Targeting transforming growth factor-β1 by methylseleninic acid/seleno-L-methionine in clear cell renal cell carcinoma: Mechanisms and therapeutic potential.Cancer treatment and research communications · 2024Article
- Exosomal Non-coding RNAs: A New Approach to Melanoma Diagnosis and Therapeutic Strategy.Current medicinal chemistry · 2024Review
- BRAF Mutations in Melanoma: Biological Aspects, Therapeutic Implications, and Circulating Biomarkers.Cancers · 2023Review
- TRPM2 Channels: A Potential Therapeutic Target in Melanoma?International journal of molecular sciences · 2023Review
- MicroRNA as a Diagnostic Tool, Therapeutic Target and Potential Biomarker in Cutaneous Malignant Melanoma Detection-Narrative Review.International journal of molecular sciences · 2023Review
- Investigating silver nanoparticles and resiquimod as a local melanoma treatment.European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V · 2023Article
- Epigenetic Mechanisms Underlying Melanoma Resistance to Immune and Targeted Therapies.Cancers · 2022Review
- BRAF Inhibitor Resistance in Melanoma: Mechanisms and Alternative Therapeutic Strategies.Current treatment options in oncology · 2022Review
- Current understanding of epigenetics role in melanoma treatment and resistance.Cancer cell international · 2022Review
- Autophagy Inhibition in BRAF-Driven Cancers.Cancers · 2021Review
- Integrated Genomics Identifies miR-181/TFAM Pathway as a Critical Driver of Drug Resistance in Melanoma.International journal of molecular sciences · 2021Article
- MicroRNA Signature in Melanoma: Biomarkers and Therapeutic Targets.Frontiers in oncology · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors at 7 institutions in 2 countries.
Lisa Koetz-PlochDepartment of Pathology, NYU School of Medicine, NYU Langone Medical Center, New York, NY, USA.
Douglas HannifordDepartment of Pathology, NYU School of Medicine, NYU Langone Medical Center, New York, NY, USA.
Igor DolgalevGenomics Technology Center, NYU School of Medicine, NYU Langone Medical Center, New York, NY, USA.
Elena SokolovaDepartment of Pathology, NYU School of Medicine, NYU Langone Medical Center, New York, NY, USA.
Judy ZhongNYU Interdisciplinary Melanoma Cooperative Group, NYU School of Medicine, NYU Langone Medical Center, New York, NY, USA.
Marta Díaz-MartínezCentro Investigaciones Biológicas, Madrid, Spain.
Emily BernsteinIcahn School of Medicine at Mount Sinai, New York, NY, USA.
Farbod DarvishianDepartment of Pathology, NYU School of Medicine, NYU Langone Medical Center, New York, NY, USA.
Keith T FlahertyMassachusetts General Hospital, Harvard University, Boston, MA, USA.
Paul B ChapmanMemorial Sloan-Kettering Cancer Center, New York, NY, USA.
Hussein TawbiMD Anderson Cancer Center, Houston, TX, USA.
Eva HernandoDepartment of Pathology, NYU School of Medicine, NYU Langone Medical Center, New York, NY, USA.ORCID 0000-0003-1023-0312
Eastern Cooperative Oncology Group · USCentro de Investigaciones Biológicas Margarita Salas · ESHarvard University · USIcahn School of Medicine at Mount Sinai · USMemorial Sloan Kettering Cancer Center · USNYU Langone Health · USThe University of Texas MD Anderson Cancer Center · US
Funding
X-RAY CRYSTALLOGRAPHYP30CA008748 · NCI · SLOAN-KETTERING INSTITUTE FOR CANCER RES · PI Nicholas D Socci · 1985 to 2026
$347.4MVaccine FacilityP30CA016087 · NCI · NEW YORK UNIVERSITY SCHOOL OF MEDICINE · PI ADRIANA HEGUY · 1985 to 2026
$83.1MRegulation and Role of miR-183-96-182 in Melanocyte Differentiation and MelanomaR01CA155234 · NCI · NEW YORK UNIVERSITY SCHOOL OF MEDICINE · PI HERNANDO, EVA · 2012 to 2016
$1.9MPrognostic and Functional Role of microRNAs in Melanoma Brain MetastasisR01CA163891 · NCI · NEW YORK UNIVERSITY SCHOOL OF MEDICINE · PI HERNANDO, EVA, OSMAN, IMAN · 2013 to 2017
$1.7MNCI NIH HHS P30 CA008748NCI NIH HHS P30 CA016087NCI NIH HHS R01 CA155234NCI NIH HHS R01 CA163891
Abstract
Melanoma patients with BRAF
Indexed as
Apoptosisbcl-2 Homologous Antagonist-Killer ProteinCell Line, TumorDrug Resistance, NeoplasmGene Expression Regulation, NeoplasticHumansMelanomaMicroRNAsProtein Kinase InhibitorsProto-Oncogene Proteins B-rafSignal TransductionTransforming Growth Factor betaBAK1 protein, humanbcl-2 Homologous Antagonist-Killer ProteinMicroRNAsMIRN125 microRNA, humanProtein Kinase InhibitorsProto-Oncogene Proteins B-rafTransforming Growth Factor betaapoptosisBRAF inhibitormelanomamicroRNAresistance
Identifiers
What OpenQuestion holds
Textmetadata
LicenceTDM
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.